DPP-4 inhibitors may prevent hypoglycemic episodes in insulin-treated type 2 diabetes (T2D), but mechanisms are unclear. 20 T2D patients treated with basal insulin and metformin (± other agents) were recruited for two randomized treatments (placebo or 100 mg/d sitagliptin) in addition to insulin glargine/metformin; 17 completed (3 women, 14 men; age 57 ± 7 yrs.; BMI 28.8 ± 3.9 kg/m2; HbA1c 7.4 ± 0.7 %). After titrating fasting plasma glucose (PG) to 90-110 mg/dl, patients were observed during a 3-day (d) inpatient period with exposure to oral glucose or lipid loads, strenuous exercise and fasting, while increasing insulin doses to 110, and 120 % of the titrated dose before d 2 and 3, respectively. Hypoglycemic episodes (PG < 70 mg/dl) were identified by measuring venous plasma glucose or symptoms, and prompted the determination of counter-regulatory hormones at the glucose nadir and 30 and 60 min later. After titrating insulin glargine, fasting PG was 112 ± 5 and 107 ± 5 mg/dl with placebo and sitagliptin treatment, respectively. Concentrations of insulin, C-peptide and counterregulatory hormones were similar during both treatments. Hypoglycemic episodes were mainly nocturnal (10 p.m. to 7 a.m.), with a similar PG nadir (65 ± 4 mg/dl) and incidence with placebo and sitagliptin (4.5 ± 3.2 vs. 4.6 ± 3.6 episodes per patient, respectively, p = 0.96). With a similar incidence of daytime (7 a.m. to 10 p.m.) chemical hypoglycemia, the incidence of symptomatic episodes was higher with sitagliptin (0.2 ± 0.4 vs. 0.0 ± 0.0, p = 0.028). Counter-regulatory responses were suppressed by sitagliptin for cortisol (p = 0.022), unchanged for glucagon, HGH, noradrenaline and prolactin, and accentuated for adrenaline (p = 0.022). Our results suggest that sitagliptin treatment augments counter-regulatory responses of adrenaline at minimal degrees of hypoglycemia. This may increase symptoms, in particular during daytime, and may offer opportunities for earlier treatment.

Disclosure

M. A. Nauck: Advisory Panel; Self; Berlin-Chemie AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk, Consultant; Self; Eli Lilly and Company, Novo Nordisk, Research Support; Self; Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk, Speaker’s Bureau; Self; Berlin-Chemie AG, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk. A. Feldmann: None. J. J. Meier: Advisory Panel; Self; AstraZeneca, MSD Corporation, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, MSD Corporation, Novo Nordisk, Sanofi. M. Nauck: None. C. Kapitza: Research Support; Self; ADOCIA, Afon Technology, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Johnson & Johnson, Julphar, Mylan N. V., Nestlé, Novo Nordisk A/S, Sanofi, Zealand Pharma A/S.

Funding

Merck Sharp & Dohme Corp

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.